Abstract: The present invention relates to a composition for detecting an epidermal cell growth factor receptor gene mutation and to a kit comprising the composition and, more specifically, to a primer and probe set composition for detecting an epidermal cell growth factor gene mutation, and to a kit for detecting an EGFR gene mutation, comprising the composition. A method according to the present invention can not only predict and diagnose responsiveness to a therapeutic agent for the prognosis of a cancer patient, but also predict a cancer metastasis or relapse Thus, the method can be useful for the purposes of determining the need to administer an anticancer therapeutic agent and guiding the direction of future treatment, and for monitoring a cancer metastasis or relapse.
Type:
Grant
Filed:
May 25, 2017
Date of Patent:
March 1, 2022
Assignee:
GENCURIX INC
Inventors:
Young Kee Shin, Bohyun Byun, Hyunjeung Choi, Joon Seok Choi, Young Ho Moon, Jong Heun Lee, Sang Rea Cho, Jee Eun Kim, Myungsun Kim
Abstract: The present invention relates to a method for selecting a gene intended to predict the prognosis for a cancer, to the selected gene for predicting the prognosis of cancer and to a kit for predicting and a method for predicting metastasis in breast-cancer patients by using the same. In the present invention, a straight forward method is used to achieve high-reliability prediction of the patient's prognosis by analysing for the genetic characteristics of early stage breast cancer, and thus the present invention can be used to advantage in prognosis diagnosis which can reduce unnecessary anticancer therapy.
Type:
Application
Filed:
July 4, 2013
Publication date:
December 26, 2013
Applicant:
Gencurix Inc
Inventors:
Young Kee Shin, Yoon La Choi, Young-Deug Kim, Eu Sel Oh, Si Eun Kim